Recent data generated from TLA sequencing of lymphoma cancer demonstrated a significant improvement over FISH (fluorescence in situ hybridization) and provided additional actionable information for clinicians.

TAK-754, an investigational AAV gene therapy for hemophilia A is currently in Phase 1 clinical study, soon to be followed by other potential gene therapies including TAK-748, an investigational gene therapy for hemophilia B. The treatment goal of gene therapy ...

Fast growing and lucrative markets such as oncology and gene therapy have mainly been the focus areas for M&A activities.

These scientific updates from the company showed off investigational and early-stage therapies as well as data from Phase 3 trials in disease states like leukemia and lymphoma.

He explained that the volcanic rock obsidian was used to make the most precise scalpels and that bringing precision to cell and gene therapies is Obsidian Therapeutics’ goal.

Cationic Antheraea pernyi Silk Fibroin-Modified Adenovirus-Mediated ING4 and IL-24 Dual Gene Coexpression Vector Suppresses the Growth of Hepatoma Carcinoma Cells Jing Qu,1 Weiwei Wang,1 Yanfei Feng,1 Longxing Niu,1 Mingzhong Li,1 Jicheng Yang,2 Yufeng Xie3 1National Engineering Laboratory for Modern Silk, College of Textile and Clothing Engineering, Soochow University, Suzhou 215123, People′s Republic of China; 2Cell and Molecular Biology Institute, College of Medicine, Soochow University, Suzhou 215123, People′s Republic of China; 3Department of Oncology, First Affiliated Hospital of Soochow University, Suzhou 215006, People′s Republic of ChinaCorrespondence: Mingzhong LiNational Engineering Laboratory for Modern Silk, College of Textile

Gene therapy treatments are intended to be one-off treatments, attacking the problem at its source.

BOSTON, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP) today reported that the Company granted a new employee an option to purchase an aggregate of 65,000 shares of Ziopharm’s common stock effective November 21, 2019.

From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully.

The company introduced a gene therapy for the blood disorder beta thalassemia, called Zynteglo, in Europe in June, but has missed the wave that has pushed biotech stocks up this fall.

The gene therapy field has learned that higher levels of stem cell depletion, which meant higher doses of busulfan, were needed to ensure long-term engraftment of the gene-modified cells and persistence of gene therapy.

About Mustang Bio Mustang Bio, Inc. (“Mustang”) is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases.

The company will use the proceeds to advance its proprietary viral vector-based gene therapy platforms and develop its two lead ophthalmic gene therapy candidates.

The researchers saw that the gene editing to disable a gene worked in up to 77% of cells grown in the laboratory and to add or repair a gene in about 4% of cells.

– Membrane bound IL-15 (mbIL15) improves anti-tumor effect of TCR-modified T cells –

From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully.

Libella Gene Therapeutics, based in Manhattan, Kansas, claims it is now offering a gene therapy to repair telomeres at a clinic in Colombia for $1 million a dose.

Hopkins team invents non-viral system for getting gene therapy into cells.

Ferring's bladder cancer gene therapy rival has new data—and they look competitive.

Under the Agreement, the JV will implement Orgenesis' POCare cell therapy platform for clinical development and commercialization of cell and gene therapies within HYGEIA Group's network of three hospitals in Greece.